These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 27933199)

  • 21. Efficacy and safety of epratuzumab in patients with moderate/severe flaring systemic lupus erythematosus: results from two randomized, double-blind, placebo-controlled, multicentre studies (ALLEVIATE) and follow-up.
    Wallace DJ; Gordon C; Strand V; Hobbs K; Petri M; Kalunian K; Houssiau F; Tak PP; Isenberg DA; Kelley L; Kilgallen B; Barry AN; Wegener WA; Goldenberg DM
    Rheumatology (Oxford); 2013 Jul; 52(7):1313-22. PubMed ID: 23542611
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and safety of repository corticotropin injection for refractory cutaneous dermatomyositis: a prospective, open-label study.
    Fernandez AP; Gallop J; Polly S; Khanna U
    Rheumatology (Oxford); 2023 Nov; ():. PubMed ID: 37941470
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Results from a multicenter, randomized, double-blind, placebo-controlled study of repository corticotropin injection for multiple sclerosis relapse that did not adequately respond to corticosteroids.
    Wynn D; Goldstick L; Bauer W; Zhao E; Tarau E; Cohen JA; Robertson D; Miller A
    CNS Neurosci Ther; 2022 Mar; 28(3):364-371. PubMed ID: 34984839
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and safety of an interleukin 6 monoclonal antibody for the treatment of systemic lupus erythematosus: a phase II dose-ranging randomised controlled trial.
    Wallace DJ; Strand V; Merrill JT; Popa S; Spindler AJ; Eimon A; Petri M; Smolen JS; Wajdula J; Christensen J; Li C; Diehl A; Vincent MS; Beebe J; Healey P; Sridharan S
    Ann Rheum Dis; 2017 Mar; 76(3):534-542. PubMed ID: 27672124
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Repository corticotropin injection in patients with rheumatoid arthritis resistant to biologic therapies.
    Fischer PA; Rapoport RJ
    Open Access Rheumatol; 2018; 10():13-19. PubMed ID: 29445306
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical, laboratory and health-related quality of life correlates of Systemic Lupus Erythematosus Responder Index response: a post hoc analysis of the phase 3 belimumab trials.
    Furie R; Petri MA; Strand V; Gladman DD; Zhong ZJ; Freimuth WW;
    Lupus Sci Med; 2014; 1(1):e000031. PubMed ID: 25396065
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Repository corticotropin injection as adjunctive therapy in patients with rheumatoid arthritis who have failed previous therapies with at least three different modes of action.
    Gillis T; Crane M; Hinkle C; Wei N
    Open Access Rheumatol; 2017; 9():131-138. PubMed ID: 28790870
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Results from a Prospective, Open-Label, Phase 4 Pilot Study of Repository Corticotropin Injection for Moderate and Severe Dry Eye Disease.
    Toyos M; Toyos R; Jodoin B; Bunch R
    Ophthalmol Ther; 2022 Jun; 11(3):1231-1240. PubMed ID: 35460497
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Repository Corticotropin Injection (Acthar
    Wirta D; McLaurin E; Ousler G; Liu J; Kacmaz RO; Grieco J
    Ophthalmol Ther; 2021 Dec; 10(4):1077-1092. PubMed ID: 34669183
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and safety of adrenocorticotropic hormone gel in refractory dermatomyositis and polymyositis.
    Aggarwal R; Marder G; Koontz DC; Nandkumar P; Qi Z; Oddis CV
    Ann Rheum Dis; 2018 May; 77(5):720-727. PubMed ID: 29237618
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Testosterone patches in the management of patients with mild/moderate systemic lupus erythematosus.
    Gordon C; Wallace DJ; Shinada S; Kalunian KC; Forbess L; Braunstein GD; Weisman MH
    Rheumatology (Oxford); 2008 Mar; 47(3):334-8. PubMed ID: 18238794
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The use of the British Isles Lupus Assessment Group (BILAG) index as a valid tool in assessing disease activity in childhood-onset systemic lupus erythematosus.
    Marks SD; Pilkington C; Woo P; Dillon MJ
    Rheumatology (Oxford); 2004 Sep; 43(9):1186-9. PubMed ID: 15226518
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Repository corticotropin for Chronic Pulmonary Sarcoidosis.
    Baughman RP; Sweiss N; Keijsers R; Birring SS; Shipley R; Saketkoo LA; Lower EE
    Lung; 2017 Jun; 195(3):313-322. PubMed ID: 28353116
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Belimumab: review of use in systemic lupus erythematosus.
    Boyce EG; Fusco BE
    Clin Ther; 2012 May; 34(5):1006-22. PubMed ID: 22464040
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Anifrolumab effects on rash and arthritis: impact of the type I interferon gene signature in the phase IIb MUSE study in patients with systemic lupus erythematosus.
    Merrill JT; Furie R; Werth VP; Khamashta M; Drappa J; Wang L; Illei G; Tummala R
    Lupus Sci Med; 2018; 5(1):e000284. PubMed ID: 30588322
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase I, randomized, double-blind, placebo-controlled, multiple intravenous, dose-ascending study of sirukumab in cutaneous or systemic lupus erythematosus.
    Szepietowski JC; Nilganuwong S; Wozniacka A; Kuhn A; Nyberg F; van Vollenhoven RF; Bengtsson AA; Reich A; de Vries DE; van Hartingsveldt B; Robinson DW; Gordon R; Hsu B
    Arthritis Rheum; 2013 Oct; 65(10):2661-71. PubMed ID: 23896980
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A phase 2, randomised, placebo-controlled clinical trial of blisibimod, an inhibitor of B cell activating factor, in patients with moderate-to-severe systemic lupus erythematosus, the PEARL-SC study.
    Furie RA; Leon G; Thomas M; Petri MA; Chu AD; Hislop C; Martin RS; Scheinberg MA;
    Ann Rheum Dis; 2015 Sep; 74(9):1667-75. PubMed ID: 24748629
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Iberdomide in patients with systemic lupus erythematosus: a randomised, double-blind, placebo-controlled, ascending-dose, phase 2a study.
    Furie RA; Hough DR; Gaudy A; Ye Y; Korish S; Delev N; Weiswasser M; Zhan X; Schafer PH; Werth VP
    Lupus Sci Med; 2022 Feb; 9(1):. PubMed ID: 35169036
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dehydroepiandrosterone treatment of women with mild-to-moderate systemic lupus erythematosus: a multicenter randomized, double-blind, placebo-controlled trial.
    Chang DM; Lan JL; Lin HY; Luo SF
    Arthritis Rheum; 2002 Nov; 46(11):2924-7. PubMed ID: 12428233
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A Retrospective Medical Record Review of Utilization Patterns and Medical Resource Use Associated with Repository Corticotropin Injection among Patients with Rheumatologic Diseases in the United States.
    Nelson WW; Philbin MJ; Gallagher JR; Heap K; Carroll S; Wan GJ
    Rheumatol Ther; 2017 Dec; 4(2):465-474. PubMed ID: 29071588
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.